... Inotek Pharmaceuticals (NASDAQ: ITEK) from Buy to Neutral, price target $2.00. Analyst Dr. Corey Davis sees a possible reverse merger coming up.
Growth Capitalist (https://growthcapitalist.com/2017/07/update-hc-wainwright-downgrades-inotek-pharmaceuticals-itek-to-neutral/)
... Inotek Pharmaceuticals (NASDAQ: ITEK) from Buy to Neutral, price target $2.00. Analyst Dr. Corey Davis sees a possible reverse merger coming up.